Academic Journals Database
Disseminating quality controlled scientific knowledge

PHARMACOKINETIC PARAMETERS TO BE EVALUATED FOR SELECTED LOW MOLECULAR WEIGHT HEPARINs IN BIOEQUIVALENCE STUDIES

ADD TO MY LIST
 
Author(s): Chaitanya Gadiko*, Satyanarayana Thota and Sudhakar K. Tippabotla

Journal: International Journal of Pharmaceutical Sciences and Research
ISSN 0975-8232

Volume: 3;
Issue: 11;
Start page: 4065;
Date: 2012;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: Low Molecular Weight Heparin | Anti-Xa | Anti-IIa | aPTT | Heptest | Pharmacodynamic marker

ABSTRACT
Bioequivalence needs to be established on healthy human volunteers for Low Molecular Weight Heparins (LMWHs) such as Dalteparin, Enoxaparin, Tinzaparin and Fondaparinux using Pharmacodynamic marker(s) for generic approval. Anti-Xa and anti-IIa activity are used to determine the activity of LMWHs (Dalteparin, Enoxaparin and Tinzaparin) and anti-Xa activity for Fondaparinux in biological samples for the assessment of its bioavailability. These are selected based on the pharmacodynamic activities of LMWHs. LMWHs exhibit their antithrombotic activity preferentially by inhibiting clotting Factor Xa, and to a lesser extent Factor IIa. On the other hand Fondaparinux is a synthetic and specific inhibitor of Factor-Xa and hencebioequivalence needs to be established for only anti-Xa activity. The pharmacodynamic data of anti-IIa activity need to be submitted for regulatory agency as supportive data of comparable therapeutic outcome for all LMWHs except Fondaparinux. In addition to the above, pharmacokinetic data of Heptest (Heparin clotting assay) and activated Partial Thromboplastin Time (aPTT) may also serve as a supportive evidence for establishing bioequivalence of LMWH formulations as there were no clear recommendations available.
Why do you need a reservation system?      Save time & money - Smart Internet Solutions